Menu
Search
|

Menu

Close
X

ZIOPHARM Oncology Inc ZIOP.OQ (NASDAQ Stock Exchange Capital Market)

4.07 USD
-- (--)
As of Mar 22
chart
Previous Close 4.07
Open --
Volume --
3m Avg Volume 513,024
Today’s High --
Today’s Low --
52 Week High 5.00
52 Week Low 1.56
Shares Outstanding (mil) 141.96
Market Capitalization (mil) 890.11
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
6
FY16
7
EPS (USD)
FY18
-0.406
FY17
-0.536
FY16
-1.322
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.54
Price to Sales (TTM)
vs sector
139.32
8.39
Price to Book (MRQ)
vs sector
--
5.27
Price to Cash Flow (TTM)
vs sector
--
24.12
Total Debt to Equity (MRQ)
vs sector
0.00
16.02
LT Debt to Equity (MRQ)
vs sector
0.00
11.35
Return on Investment (TTM)
vs sector
-45.27
13.82
Return on Equity (TTM)
vs sector
--
15.24

EXECUTIVE LEADERSHIP

David Mauney
President, Since 2018
Salary: $103,077.00
Bonus: $36,158.00
Laurence Cooper
Chief Executive Officer, Director, Since 2018
Salary: $500,000.00
Bonus: $875,000.00
Kevin Lafond
Principal Financial Officer, Chief Accounting Officer, Senior Vice President - Finance, Treasurer, Since 2013
Salary: $275,000.00
Bonus: $84,219.00
Lynn Ferrucci
Senior Vice President - Human Resources, Facilities and Administration, Since
Salary: --
Bonus: --
Scott Tarriff
Non-Executive Lead Independent Director, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

One First Avenue Parris Building
, Navy Yard Plaza
BOSTON   MA   02129

Phone: +1617.2591970

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

SPONSORED STORIES